ANI Pharmaceuticals Inc
ANIP
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.71B
Close$
$-54.62
171.1% downside
Current Fair Value
171.1% downsideOvervalued by 171.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.71 Billion |
|---|---|
| Enterprise Value | $1.69 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $3.5 |
| Beta | 0.46 |
| Outstanding Shares | 21,158,000 |
Return
| Return on Equity | 18.55% |
|---|---|
| Return on Assets | 7.42% |
| Return on Invested Capital | 12.67% |
Valuation & Multiples
| P/E Ratio | 15.6 |
|---|---|
| PEG | 7.1 |
| Price to Sales | 1.67 |
| Price to Book Ratio | 2.75 |
| Enterprise Value to Revenue | 1.72 |
| Enterprise Value to EBIT | 11 |
| Enterprise Value to Net Income | 15 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.56 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$2.01
Average shareholder expectationRevenue Estimate
$260.13 M
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$2.41
Average shareholder expectationRevenue Estimate
$280.06 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 24.0444▲ 2198.32% |
|---|---|
| Total Calls | 9,000▼ 95.56% |
| Total Puts | 216,400▼ 48.16% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 110.75%▼ 5.91% |
|---|---|
| Total Invested | $1.92B▲ 6.65% |
| Investors Holding | 310▲ 23.00% |
ESG Score
No data
About ANI Pharmaceuticals Inc
CEO: Patrick Walsh ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include ...